IPP Bureau
T-CURX gets Swissmedic nod for first human trial of non-viral CAR-T therapy
By IPP Bureau - June 15, 2026
Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform
Ramkrishna CARE Hospitals’s dedicated cancer institute to open in August 2026
By IPP Bureau - June 15, 2026
The new institute will strengthen oncology infrastructure in central India with advanced radiation therapy, multidisciplinary expertise, and comprehensive cancer care services
Dr Reddy’s launches first-to-market generic Bosutinib in US oncology push
By IPP Bureau - June 15, 2026
Dr Reddy’s has partnered with MSN Laboratories Private Limited on the product, with Dr Reddy’s holding exclusive US marketing rights while MSN leads development and manufacturing
Arihant Innochem launches state-of-the-art research & innovation centre in Navi Mumbai
By IPP Bureau - June 15, 2026
The new facility aims to accelerate formulation science and application-led research across pharma, biopharma, nutraceuticals, personal care, and home care segments
Leprosy elimination drive intensifies as Indian govt pushes high-burden states toward zero transmission goal
By IPP Bureau - June 15, 2026
Patnaik stressed early diagnosis, rapid treatment, and aggressive surveillance as the backbone of elimination efforts
Cohere Health’s Global Innovation Centre recognized as impactful at ET Edge GCC Summit
By IPP Bureau - June 15, 2026
Award highlights Hyderabad-based innovation hub’s role in advancing healthcare technology, clinical intelligence, and global operational excellence
Cohance Lifesciences shareholders back Umang Vohra as Chairman and Group CEO
By IPP Bureau - June 15, 2026
Postal ballot also clears remuneration proposal and new ESOP 2026 scheme, strengthening the company’s leadership and talent retention strategy
Suven Life Sciences to showcase narcolepsy program Samelisant at SLEEP 2026
By IPP Bureau - June 14, 2026
Samelisant will be the centerpiece of Suven’s scientific presence
Alembic secures USFDA nod for Tretinoin Cream strengthening generics portfolio
By IPP Bureau - June 14, 2026
The approval clears the company to market a generic version that is therapeutically equivalent to Retin-A Cream
Breakthrough approval in prostate cancer for AstraZeneca therapy
By IPP Bureau - June 14, 2026
The decision was driven by results from the Phase III CAPItello-281 trial,
India clears major milestone in cervical cancer fight with validation of first indigenous HPV DNA test
By IPP Bureau - June 14, 2026
Cervical cancer remains one of the leading causes of cancer deaths among women in India
Centre intensifies push for zero leprosy transmission
By IPP Bureau - June 13, 2026
Health Ministry reviews progress, highlights targeted interventions in high-burden states, and calls for stronger surveillance and stigma reduction to achieve a leprosy-free India
India validates first indigenous HPV DNA test for cervical cancer screening
By IPP Bureau - June 13, 2026
Molbio Diagnostics' Truenat HPV-HR Plus becomes the world's first formally validated reduced-valency HPV test, meeting WHO-IARC standards
Ryvu advances romaciclib program as FDA clears AML trial expansion
By IPP Bureau - June 13, 2026
The regulatory decision follows promising results from RIVER-81
Novo Nordisk confirms cyber breach after hackers access personal data
By IPP Bureau - June 13, 2026
Despite the disruption, the company stressed that “our core business operations are not impacted and remain up and running.
